Matthew Barcus
Stock Analyst at Chardan Capital
(2.45)
# 2,531
Out of 5,090 analysts
21
Total ratings
25%
Success rate
27.58%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Barcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZURA Zura Bio | Maintains: Buy | $12 → $10 | $3.87 | +158.40% | 3 | Mar 26, 2025 | |
| QURE uniQure | Maintains: Buy | $45 → $27 | $23.09 | +16.93% | 4 | Jun 22, 2023 | |
| XLO Xilio Therapeutics | Reiterates: Buy | $7 | $0.74 | +842.76% | 3 | May 30, 2023 | |
| IMVT Immunovant | Maintains: Buy | $21 → $32 | $22.94 | +39.49% | 4 | May 23, 2023 | |
| PPBT Purple Biotech | Reiterates: Buy | $220 | $0.85 | +25,861.77% | 3 | May 17, 2023 | |
| ANIX Anixa Biosciences | Reiterates: Buy | $9 | $4.74 | +89.87% | 3 | Apr 18, 2023 | |
| IMNM Immunome | Maintains: Buy | $9 → $8 | $20.12 | -60.24% | 1 | Mar 17, 2023 |
Zura Bio
Mar 26, 2025
Maintains: Buy
Price Target: $12 → $10
Current: $3.87
Upside: +158.40%
uniQure
Jun 22, 2023
Maintains: Buy
Price Target: $45 → $27
Current: $23.09
Upside: +16.93%
Xilio Therapeutics
May 30, 2023
Reiterates: Buy
Price Target: $7
Current: $0.74
Upside: +842.76%
Immunovant
May 23, 2023
Maintains: Buy
Price Target: $21 → $32
Current: $22.94
Upside: +39.49%
Purple Biotech
May 17, 2023
Reiterates: Buy
Price Target: $220
Current: $0.85
Upside: +25,861.77%
Anixa Biosciences
Apr 18, 2023
Reiterates: Buy
Price Target: $9
Current: $4.74
Upside: +89.87%
Immunome
Mar 17, 2023
Maintains: Buy
Price Target: $9 → $8
Current: $20.12
Upside: -60.24%